跳至主要内容
临床试验/IRCT20110512006463N3
IRCT20110512006463N3已完成3 期

A comparison of complication & major cardiovascular events of bolus eptifibatide versus bolus plus infusion of eptifibatide in Primary PCI in patients with acute ST-elevation myocardial infarction

Deputy of research and technology of Alborz University of Medical Sciences0 个研究点目标入组 163 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
163

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients with symptoms of ischemic heart attack that last no longer than 12 hours with 1 mm ST elevation in at least 2 limb leads or 2 mm ST elevation in at least 2 precordial leads who are candidates for Primary PCI intervention.

排除标准

  • Not acceptance of informed consent
  • History of sensitivity to eptifibatide, heparin or aspirin
  • Recent treatment with warfarin (INR>2), fibrinolythics or other IIbIIIa inhibitors
  • Platelet <100000/mcL
  • Known bleeding disorder
  • History of ischemic cerebrovascular accident in previous 30 days
  • History of hemorrhagic cerebrovascular accident
  • Abnormal bleeding in recent 30 days.
  • Major surgery in previous 6 weeks
  • Renal failure with dependency to hemodialysis
  • Uncontrolled hypertension (SBP>200mmHg, or DBP>110mmHg)

研究者

发起方
Deputy of research and technology of Alborz University of Medical Sciences

相似试验

Bolus eptifibatide versus bolus plus infusio | 临床试验